We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals
BDRX

3 hedge funds and large institutions have $169K invested in Biodexa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

255% more capital inflows, than outflows

Capital inflows: $204K | Capital outflows: $57.4K

200% more funds holding

Funds holding: 1 → 3 (+2)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

5.11% less ownership

Funds ownership: 5.11% → 0% (-5.1%)

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Boothbay Fund Management
Boothbay Fund Management
New York
+$136K
2
Bank of America
Bank of America
North Carolina
+$34K
3
Renaissance Technologies
Renaissance Technologies
New York
+$34K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$57.2K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$254

BDRX Hedge Fund Activity: Q4 2023 in Review

3 of the 6,878 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q4 2023, worth a combined $169K — up 187% from $58.9K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BDRX positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $136K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $57.2K sold.

  • 3 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q4 2023, up from 1 in Q3 2023.
  • Funds reported $169K of Biodexa Pharmaceuticals stock for Q4 2023, up 187% quarter-over-quarter.
  • 3 funds opened new Biodexa Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +2 holders.
  • The largest Biodexa Pharmaceuticals buyer in Q4 2023 was Boothbay Fund Management, an estimated $136K added.
  • The largest Biodexa Pharmaceuticals seller in Q4 2023 was Susquehanna International Group, an estimated $57.2K sold.

Based on aggregated 13F filings for Q4 2023.